Notice: This company has been marked as potentially delisted and may not be actively trading. Fusion Pharmaceuticals (FUSN) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get the Latest News and Ratings for FUSN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Fusion Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up FUSN Analyst Ratings Over TimeTypeCurrent Forecast11/14/23 to 11/13/241 Month Ago10/15/23 to 10/14/243 Months Ago8/16/23 to 8/15/241 Year Ago11/14/22 to 11/14/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)7 Buy rating(s)Hold13 Hold rating(s)13 Hold rating(s)13 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$20.25$20.25$20.25$11.17Forecasted Upside-6.03% Downside-6.03% Downside-6.03% Downside167.79% UpsideConsensus RatingHoldHoldHoldBuy Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. FUSN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History FUSN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Fusion Pharmaceuticals Stock vs. The CompetitionTypeFusion PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.07 2.80 2.50Consensus RatingHoldModerate BuyHoldPredicted Upside-6.03% Downside26,392.09% Upside7.73% UpsideNews Sentiment RatingNeutral NewsSee Recent FUSN NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails4/16/2024TD Cowen4 of 5 stars Reiterated RatingBuy ➝ Hold3/20/2024Bloom Burton2 of 5 starsD. MartinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/20/2024B. Riley4 of 5 starsY. ZhiSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $23.00+8.75%3/20/2024JonestradingSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Hold3/20/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Sector Perform$16.00 ➝ $21.00-0.85%3/19/2024Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingF. KhurshidSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform Get the Latest News and Ratings for FUSN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 3/19/2024Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Hold$11.00 ➝ $21.00-0.05%3/19/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Hold$10.00 ➝ $21.00+0.05%3/19/2024Raymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingStrong-Buy ➝ Market Perform3/19/2024Brookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingK. DolliverSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/19/2024William BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. HsiehSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/19/2024WedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. NierengartenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$24.00+14.29%3/19/2024Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Market Perform$17.00 ➝ $21.00+97.37%1/5/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform ➝ Outperform$13.00 ➝ $15.00+77.94%1/27/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight$19.00 ➝ $10.00+201.20%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:15 AM ET. FUSN Forecast - Frequently Asked Questions What is Fusion Pharmaceuticals' forecast for 2025? According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Fusion Pharmaceuticals is $20.25, with a high forecast of $24.00 and a low forecast of $15.00. Should I buy or sell Fusion Pharmaceuticals stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares. Does Fusion Pharmaceuticals's stock price have much downside? According to analysts, Fusion Pharmaceuticals's stock has a predicted downside of -6.03% based on their 12-month stock forecasts. Do Wall Street analysts like Fusion Pharmaceuticals more than its competitors? Analysts like Fusion Pharmaceuticals less than other "medical" companies. The consensus rating for Fusion Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FUSN compares to other companies. Stock Forecasts and Research Tools Related Companies YMAB Stock Forecast MGTX Stock Forecast ACLX Stock Forecast ADMA Stock Forecast KRYS Stock Forecast DNLI Stock Forecast IMVT Stock Forecast CRSP Stock Forecast IBRX Stock Forecast KYMR Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. This page (NASDAQ:FUSN) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
